Mode
Text Size
Log in / Sign up

In lung cancer patients, immune-checkpoint inhibitors were associated with a 16.4% incidence of thyroid irAEsThyroid Trouble Might Mean Better Lung Cancer Response

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that thyroid irAEs may correlate with favorable tumor response and longer duration of response in lung cancer patients receiving ICIs.

This retrospective analysis included 420 patients with lung cancer treated with immune-checkpoint inhibitors (ICIs) at the oncology unit of IRCCS Policlinico San Matteo in Pavia between March 2016 and December 2024. The study compared patients with and without thyroid dysfunction to evaluate the incidence and characteristics of thyroid irAEs, alongside secondary outcomes including objective response, progression-free survival (PFS), and overall survival (OS).

The incidence of thyroid irAEs was 16.4% (69 of 420 patients). Grade distribution showed 31.9% were grade 1, 66.7% were grade 2, and 1.4% were grade 3. Of the patients with thyroid irAEs, 65.2% required thyroid replacement therapy, and 13% received steroids. Male sex was associated with a lower incidence of thyroid irAEs (p 0.050), whereas non-small cell lung cancer (NSCLC) NOS histology was associated with a higher risk (p 0.021). Disease stage and treatment line were not significantly correlated with thyroid irAEs.

Patients who developed thyroid irAEs were more likely to achieve an objective response (CR/PR) (p 0.028) and had a significantly longer duration of response (median 34 vs 17 months, p 0.047). Those with progressive disease (PD) had a lower incidence of thyroid irAEs compared to stable disease (SD) (p 0.010). No significant associations were found between thyroid irAEs and PFS (HR 1.08, p 0.66) or OS (HR 1.02, p 0.89). The primary limitation is the single-center retrospective design, which precludes definitive causal conclusions regarding the prognostic value of these events.

The Hidden Signal in Your Body

Imagine you are driving a car with a powerful engine. You press the gas pedal, and the car speeds up. But sometimes, the engine gets a little hot and makes a strange noise. You might worry the car is breaking down. But what if that noise actually meant the engine was running at peak power?

For many people with lung cancer, their doctors use special medicines called immune checkpoint inhibitors. These drugs help your own immune system fight the cancer. But these drugs can also make your immune system go into overdrive. Sometimes, this overactive system attacks your thyroid gland. This causes problems like feeling tired or gaining weight.

Doctors usually call this an immune-related adverse event. Patients often feel scared when these side effects start. They worry the drug is hurting them. But a new look at patient data suggests something different might be happening.

Lung cancer is the most common cause of cancer death around the world. Many people live with this disease for years thanks to new treatments. Immune checkpoint inhibitors have changed the game. They work in many different situations.

However, these drugs come with a cost. About one in six patients develop thyroid problems. Most of these are mild, like a slightly low thyroid hormone level. Doctors usually treat them with simple hormone replacement pills.

The problem is that patients often stop taking their cancer drug because of these side effects. They think the drug is failing or hurting them. This can lead to stopping a treatment that might be working very well. Understanding the connection between side effects and success is vital for patient care.

The Surprising Shift

For a long time, doctors thought any side effect meant the drug was too strong or not right for that patient. The idea was that if your immune system was attacking your thyroid, it was just causing damage.

But here is the twist. A recent study looked at 420 patients treated at a major hospital in Italy. They tracked who had thyroid issues and who did not. The results were unexpected.

Patients who developed thyroid problems were more likely to have their cancer shrink. In fact, their response to the drug was better than those without the side effect. Their cancer stayed under control for a longer time.

Think of your immune system like a security guard. The cancer drug tells the guard to wake up and catch the bad guys. Sometimes, the guard gets so excited that it mistakes your own thyroid gland for a bad guy.

This mistake shows the guard is very active. It is working hard. If the guard is working hard enough to attack the thyroid, it is likely also working hard against the cancer cells. The side effect is a sign of a strong immune response.

Researchers reviewed records of 420 lung cancer patients. These patients were treated between March 2016 and December 2024. They looked at who got thyroid issues and who did not. They also checked how long the cancer stayed under control.

The study found that 69 patients, or about 16 percent, developed thyroid problems. Most of these happened within the first six months of treatment. The majority were mild cases that did not require strong steroid shots.

The most important finding was about the cancer response. Patients with thyroid issues were more likely to see their tumors shrink. Their cancer response was significantly better than those without the side effect.

Also, the time their cancer stayed under control was longer. On average, patients with thyroid issues had their cancer controlled for 34 months. Those without the issue had it controlled for only 17 months.

However, having the side effect did not change how long the patient lived overall. The study looked at total survival time and found no difference between the two groups. The side effect did not hurt the patient's life span.

This doesn't mean this treatment is available yet.

The Catch

There is a catch. This study looked at past records. It shows a pattern, but it does not prove cause and effect. We do not know for sure why this happens. It could be that people who tolerate the drug well get the side effect, or it could be the drug itself causing both.

Male patients were less likely to get the thyroid issue. Patients with a specific type of lung cancer were more likely to get it. But the stage of the cancer did not matter.

Doctors are excited about this finding. It changes how they view side effects. Instead of seeing a thyroid issue as a reason to stop a drug, it might be a sign to keep going.

This fits into a bigger picture of understanding how the immune system works. Some side effects are actually good news. They show the medicine is doing its job. This helps doctors make better decisions for each patient.

If you are taking these drugs, do not panic if you feel tired or gain weight. Talk to your doctor about checking your thyroid. If you have a mild issue, you might be able to keep taking your cancer medicine.

Do not stop your treatment without asking your doctor. A side effect might mean your treatment is working well. Your doctor can manage the thyroid issue with simple pills while you keep fighting the cancer.

This study has limits. It looked at patients at one hospital. The results might be different at other places. Also, the study looked at past data, which means it cannot prove the side effect causes the better results. More research is needed to confirm this pattern.

Scientists will need to run more studies to confirm these findings. They want to see if this pattern holds true for many different patients. If confirmed, doctors might use thyroid issues as a sign that a drug is working.

This could change how doctors talk to patients. They might explain that a small side effect could be a good thing. It takes time for research to move from a study to standard practice. But this hope gives patients a new way to understand their treatment.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundLung cancer is the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have radically changed the treatment of lung cancer gradually entering all treatment settings. Alongside their clinical benefits, ICIs are associated with immune-related adverse events (irAEs), among which endocrine toxicities, particularly thyroid dysfunctions, represent some of the most frequent.MethodsWe conducted a retrospective analysis of 420 lung cancer patients referred to the oncology unit of IRCCS Policlinico San Matteo in Pavia, between March 2016 and December 2024. Clinical and treatment-related data were reviewed to identify thyroid irAEs. Comparative analyses between patients with and without thyroid dysfunction were performed using descriptive statistics and survival outcomes.ResultsAmong 420 lung cancer patients treated with ICIs, 69 (16.4%) developed thyroid irAEs. Most events occurred in the first 6 months, and the majority were grade 1–2 (G1 31.9%, G2 66.7%, G3 1.4%). Thyroid replacement therapy was required in 65.2%, while steroids were used in 13%.Male sex was associated with a lower incidence of thyroid irAEs (p 0.050), non-small cell lung cancer (NSCLC) not otherwise specified (NOS) histology was associated with a higher risk (p 0.021). Disease stage and treatment line were not significantly correlated.Patients experiencing thyroid irAEs were more likely to achieve an objective response (CR/PR) compared with those without (p 0.028). Moreover, patients with PD as best response showed a significantly lower incidence of thyroid irAEs compared to those with SD (p 0.010). Duration of response was significantly longer in patients with thyroid irAEs (median 34 vs 17 months; p 0.047).Time-dependent Cox models did not demonstrate a significant association between thyroid irAEs and progression-free survival - PFS (HR 1.08, p 0.66) or overall survival – OS (HR 1.02, p 0.89).ConclusionsThe occurrence of thyroid irAEs correlated with better tumor response rates and prolonged duration of response, while not significantly impacting PFS or OS. These findings support the hypothesis that thyroid irAEs may serve as a favorable immunologic and prognostic biomarker in the context of ICI therapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.